Sinclair Dunlop - May 18, 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for A. Sinclair Dunlop
Stock symbol
APLS
Transactions as of
May 18, 2021
Transactions value $
-$8,558,129
Form type
4
Date filed
5/20/2021, 04:53 PM
Next filing
Jun 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$3.32M -64.2K -36.73% $51.66 111K May 18, 2021 See Footnote F1, F9
transaction APLS Common Stock Sale -$748K -14.2K -12.86% $52.63 96.3K May 18, 2021 See Footnote F2, F9
transaction APLS Common Stock Sale -$1.96M -36.4K -37.77% $53.78 59.9K May 18, 2021 See Footnote F3, F9
transaction APLS Common Stock Sale -$1.22M -22.3K -37.23% $54.57 37.6K May 18, 2021 See Footnote F4, F9
transaction APLS Common Stock Sale -$62.4K -1.2K -0.37% $52.01 319K May 18, 2021 See Footnote F5, F10
transaction APLS Common Stock Sale -$556K -10.4K -3.25% $53.50 309K May 18, 2021 See Footnote F6, F10
transaction APLS Common Stock Sale -$43.2K -800 -0.26% $54.02 308K May 18, 2021 See Footnote F7, F10
transaction APLS Common Stock Sale -$381K -7.61K -2.47% $50.00 301K May 19, 2021 See Footnote F10
transaction APLS Common Stock Sale -$278K -5.77K -15.34% $48.10 31.9K May 20, 2021 See Footnote F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction involved a sale of shares held by MASA Life Science Ventures, LP ("MASA"). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.16 to $52.15. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (4) to this Form 4.
F2 The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.16 to $53.12.
F3 The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.16 to $54.15.
F4 The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.16 to $54.94.
F5 The reported transaction involved a sale of shares held by Epidarex Capital I, LP ("Epidarex"). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.00 to $52.03. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (7) to this Form 4.
F6 The reported transaction involved a sale of shares held by Epidarex. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.00 to $53.99.
F7 The reported transaction involved a sale of shares held by Epidarex. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.00 to $54.04.
F8 The reported transaction involved a sale of shares held by MASA. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.00 to $48.50.
F9 The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.
F10 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.